1. Background {#sec106742}
=============

Methicillin-resistant *Staphylococcus aureus* (MRSA) continues to be a major cause of nosocomial infections as it adapts rapidly to selective pressures imparted by the human host ([@A16998R1]). Mobile genetic elements play a central role in this adaptation process by encoding virulence factors and molecules that confer resistance to antibiotics, including the gene that confers resistance to beta-lactam antibiotics in MRSA ([@A16998R1]). Methicillin resistance in *S. aureus* is caused by the expression of PBP2a encoded by the *mec*A gene, which is located on a genetic element called the staphylococcal cassette chromosome (SCC) ([@A16998R2]).The SCC*mec* is a group of mobile DNA elements integrated into the chromosome of MRSA. To date, 11 types of the SCC*mec* have been reported ([@A16998R2]). The distribution of the 3 types of SCC*mec* (i.e. types I, II, and III) in the world has been shown, and they were originally described in hospital-acquired MRSA isolates ([@A16998R3]-[@A16998R5]). Also, types IV and V have been reported in a community-acquired MRSA isolate ([@A16998R5], [@A16998R6]). The rest of them were reported outspread in some areas ([@A16998R2]). MRSA isolated from hospital-acquired MRSA is usually resistant to multiple antibiotics, and it typically contains larger SCC*mec*.

Nosocomial infections are an important health problem worldwide due to multidrug-resistant MRSA ([@A16998R7], [@A16998R8]). Our understanding from MRSA typing and resistance genes which it expresses and the pattern of its antimicrobial resistance can provide useful information toward optimizing infection control and clinical therapy in the future. In light of previous data showing that all MRSA isolates contain specific types of the SCC*mec*, sequence-based methods can be used to compare the results obtained at different places and times and find their relationship with the origin of the infections ([@A16998R2]). The emergence of MRSA from Iran with a higher prevalence compared to the reports from neighboring countries in the Middle East calls for a great and urgent effort to understand MRSA resistance mechanisms and its current antimicrobial profile for the prevention and the selection of appropriate treatment ([@A16998R9]).

2. Objectives {#sec106743}
=============

The aim of this study was to evaluate the presence of predominant SCC*mec* type/s present among clinical isolates from our regional hospitals in a large city in the southwest of Iran, Shiraz.

3. Materials and Methods {#sec106747}
========================

3.1. Bacterial Strains {#sec106744}
----------------------

This cross-sectional study was conducted between October 2012 and March 2013 from two hospitals, Nemazee and Faghihi, in Shiraz, a major city in the southwest of Iran. Nemazee and Faghihi hospitals are two major tertiary care hospitals with 1000 beds, affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. A total of 345 *S. aureus* isolates were obtained from the clinical specimens of the two mentioned hospitals. Specimens were collected from different wards in the hospitals. Outpatient specimens and duplicate isolates were not included. The isolates were identified as *S. aureus* using standard procedures (colony morphology, Gram stain, catalase activity, growth on Mannitol salt agar, DNase test, and tube coagulase) and stored at -70°C for long-term preservation.

The MRSA isolates were screened based on resistance to Cefoxitin (30 μg) discs (MAST, UK) by the disc diffusion method according to the guidelines of The Clinical and Laboratory Standards Institute (CLSI) (10). The isolates resistant to Cefoxitin were further tested for the presence of the *mec*A gene. Totally, 146 confirmed MRSA isolates were obtained from the sputum (58), blood (20), wound (18), urine (14), pus (8), endotracheal tube (6), and 22 other specimens.

3.2. Antimicrobial Susceptibility Testing {#sec106745}
-----------------------------------------

Susceptibility profiles were determined to Ampicillin, Gentamicin, Erythromycin, Tetracycline, Ciprofloxacin, Clindamycin, Teicoplanin, Co-Trimoxazole (SXT), Chloramphenicol, Rifampicin, Linezolid, Synercid^®^, and Vancomycin antibiotic discs (MAST, UK) by the disc diffusion method according to the guidelines of the CLSI on Muller-Hinton agar (Oxoid, UK). *S. aureus* ATCC 25923, which is a Methicillin-sensitive *S. aureus*, was used in this study as the control strain in antibacterial susceptibility testing. The interpretation of the diameters of the zones of inhibition was done according to the guidelines of the CLSI ([@A16998R10]). Inducible Clindamycin resistance was also detected using the D-test method described by the guidelines of the CLSI ([@A16998R10]).

3.3. DNA Extraction and Molecular Typing {#sec106746}
----------------------------------------

Bacterial whole DNA was extracted from the MRSA isolates using the small-scale phenol-chloroform extraction method and was utilized as polymerase chain reaction (PCR) templates ([@A16998R11]). The SCC*mec* typing was optimized to use PCR experiments via a multiplex PCR protocol described for the SCC*mec* types I-V by Zhang et al. ([@A16998R12]), with the exception of the SCC*mec* type IV, which was used as a specific primer designed by Oliveira and de Lencastre ([@A16998R13]). Also, the *mec*A gene detection was amplified using a primer described by Zhang et al. ([@A16998R12]). All the primers used in the current study were manufactured by CinnaGen, Iran.

The PCR amplifications were performed in a DNA Thermal Cycler 5530 (Eppendorf Master, Germany). The PCR products were resolved by electrophoresis in 3% agarose gels at 70V and band was observed by UV irradiation ([Figure 1](#fig20406){ref-type="fig"}). The following MRSA reference strains were used as controls: COL; N315; 85/2082; and JCSC/4469 for the SCC*mec* types I, II, III, and IV, respectively. All the reference strains were kindly provided by the Professor Alborzi Clinical Microbiology Research Center, Shiraz, Iran. The DNA sequencing was performed (BIONEER, South Korea) to confirm the presence of the SCC*mec* I genes in a subset of 3 positive isolates for the SCC*mec* type I in PCR.Statistical analysis was performed using the SPSS software (version 19.0). The chi-square test or the Fisher's exact test was conducted to analyze the results. A P value \< 0.05 was regarded as statistically significant.

![A Representative Gel Image of SCC*mec* Typing by Polymerase Chain Reaction\
C-: negative control (distilled water); lane 1: SCC*mec* type I (COL); lane 2: SCC*mec* type II (N315); lane 3: SCC*mec* type 3 (85/2082); lane 4: SCC*mec* type IV (JCSC/4469); M: 100 bp ladder; and 147 bp bands belonged to the *mec*A gene as positive control for the MRSA isolates.](jjm-08-06-16998-g001){#fig20406}

4. Results {#sec106748}
==========

Of the 345 *S. aureus* isolates obtained from Nemazee and Faghihi hospitals between 2012 and 2013, 146 (42.3%) were Methicillin resistant according to the disc diffusion and the *mec*A analysis.

For all the 146 MRSA isolates, the SCC*mec* types were assigned by PCR. It was revealed that the SCC*mec* type I was the predominant type with 86 (58.9%) samples, followed by the SCC*mec* type II with 29 (19.9%), type III with 16 (11.0%), and type IV with 12 (8.2%) samples, respectively. Three (2.1%) MRSA isolates remained untypeable. The SCC*mec* type I MRSA isolates were significantly (P \< 0.001) recovered as the predominant type from 16 (80.0%) blood and 39 (67.2%) sputum samples, while the SCC*mec* type II isolates were mostly (13 \[44.8%\]) isolated from the sputum samples (P \< 0.001). Also, most of the MRSA isolates recovered from skin belonged to the SCC*mec* types II and III (P \< 0.001) ([Table 1](#tbl27372){ref-type="table"}).

###### Frequency of Different SCC*mec* Types of Methicillin-Resistant *Staphylococcus aureus* Isolated From Clinical Specimens ^[a](#fn26420){ref-type="table-fn"}^

  SCC*mec* Types, Source                                                                   I, n = 86   II, n = 29   III, n = 16   IV, n = 12   Untypeable, n = 3   Total, n = 146
  ---------------------------------------------------------------------------------------- ----------- ------------ ------------- ------------ ------------------- ----------------
  **Sputum** ^**[b](#fn26421){ref-type="table-fn"},[c](#fn26422){ref-type="table-fn"}**^   39 (45.3)   13 (44.8)    3 (18.7)      2 (16.7)     1 (33.3)            58 (39.7)
  **Blood** ^**[b](#fn26421){ref-type="table-fn"}**^                                       16 (18.6)   1 (3.4)      1 (6.3)       2 (16.7)     0 (0)               20 (13.7)
  **Wound**                                                                                10 (11.6)   5 (17.2)     1 (6.3)       2 (16.7)     0 (0)               18 (12.3)
  **Urine**                                                                                5 (5.8)     2 (6.9)      3 (18.7)      3 (25.0)     1 (33.3)            14 (9.6)
  **Skin** ^**[d](#fn26423){ref-type="table-fn"}**^                                        1 (1.2)     2 (6.9)      4 (25.0)      1 (8.3)      0 (0)               8 (5.5)
  **Endotracheal tube**                                                                    2 (2.3)     0 (0)        2 (12.5)      1 (8.3)      1 (33.3)            6 (4.1)
  **Other** ^**[e](#fn26424){ref-type="table-fn"}**^                                       13 (15.1)   6 (20.7)     2 (12.5)      1 (8.3)      0 (0)               22 (15.1)

^a^ Data are presented by No. (%).

^b^ Isolates containing the SCC*mec* type I were significantly recovered from the blood and sputum samples (P \< 0.001).

^c^ Majority of the SCC*mec* type II isolates were significantly recovered from the sputum samples (P \< 0.001).

^d^ Majority of the MRSA isolates recovered from skin significantly belonged to the SCC*mec* types II and III (P \< 0.001).

^e^ Throat (4); Body fluid (4); Nose (3); Eye (3); Cerebrospinal fluid (3); Axillary (3); Plural (2).

There were no significant differences in the detected SCC*mec* type frequencies between the two hospitals, except for the SCC*mec* type II MRSA isolates, which had a higher prevalence rate in Faghihi Hospital (P \< 0.05). The results of antibacterial susceptibility tests for the MRSA isolates showed that all the isolates were resistant to Ampicillin. Moreover, all of them were sensitive to Linezolid, Teicoplanin, Synercid^®^, and Vancomycin ([Table 2](#tbl27373){ref-type="table"}).

###### Antibiotic Resistance Pattern of MRSA isolates among the diffident SCC*mec* Types ^[a](#fn26425){ref-type="table-fn"}^

  Resistance, Antibiotics                                       I, n = 86   II, n = 29   III, n = 16   IV ^[b](#fn26426){ref-type="table-fn"}^, n = 12   Untypeable, n = 3   Total, n = 146
  ------------------------------------------------------------- ----------- ------------ ------------- ------------------------------------------------- ------------------- ----------------
  **Ciprofloxacin**                                             85 (98.8)   29 (100)     16 (100)      0 (0)                                             0 (0)               130 (89.0)
  **Gentamycin** ^**[c](#fn26427){ref-type="table-fn"}**^       84 (97.7)   28 (96.6)    12 (75.0)     0 (0)                                             0 (0)               124 (84.9)
  **Clindamycin**                                               83 (96.5)   25 (86.2)    16 (100)      3 (25.0)                                          1 (33.3)            128 (87.7)
  **Erythromycin**                                              83 (96.5)   25 (86.2)    16 (100)      3 (25.0)                                          1 (33.3)            128 (87.7)
  **Tetracycline**                                              79 (91.9)   28 (96.6)    16 (100)      6 (50.0)                                          2 (66.7)            131 (89.7)
  **Rifampin** ^**[c](#fn26427){ref-type="table-fn"}**^         70 (81.4)   21 (72.4)    6 (37.5)      0 (0)                                             0 (0)               97 (66.4)
  **Co-trimoxazole** ^**[d](#fn26428){ref-type="table-fn"}**^   16 (18.6)   7 (24.1)     11 (68.7)     0 (0)                                             0 (0)               34 (23.3)
  **Chloramphenicol**                                           2 (2.3)     1 (3.4)      0 (0)         0 (0)                                             1 (33.3)            4 (2.7)

^a^ Data are presented by No. (%).

^b^ Isolates containing the SCCmec type IV were significantly more sensitive than the other types (P \< 0.001).

^c^ Isolates that carried the SCC*mec* types I and II significantly had a greater resistance to Gentamicin and Rifampin than the isolates containing the SCC*mec* type III (P \< 0.05).

^d^ A significant difference was seen for susceptibility to Co-trimoxazole between the isolates carrying the SCC*mec* types I and II and the SCC*mec* type III (P \< 0.05).

Among the clinical specimens, the isolates recovered from skin showed a significantly higher resistance rate than the urine samples (P \< 0.05). The MRSA isolates that carried the SCC*mec* types I and II revealed a significantly greater resistance to Gentamicin and Rifampin than the isolates containing the SCC*mec* type III (P \< 0.05). Also, a significant difference was seen for susceptibility to SXT between the SCC*mec* types I and II MRSA isolates and the SCC*mec* type III, which was more resistant (P \< 0.05). Overall, the MRSA isolates containing the SCC*mec* type IV were more sensitive than the other types, especially to antibiotics including Ciprofloxacin, Gentamicin, Rifampin, SXT, and Chloramphenicol. Also, multidrug-resistance was significantly lower in the SCC*mec* type IV than in the SCC*mec* types I, II, and III, which were mostly resistant to more than 5 antibiotics (P \< 0.001) ([Figure 2](#fig20407){ref-type="fig"}).

![Comparison of the Prevalence of Multidrug-Resistant Isolates between the Different SCC*mec* Types\
Antibiotic No, represents the mentioned numbers of any of the following antibiotics: Ampicillin (AMP), Gentamycin (GEN), Erythromycin (ERY), Tetracycline (TCN), Ciprofloxacin (CPX), Clindamycin (CLIN), Co-trimoxazole (SXT), and Rifampicin (RIPE). (Results of the untypeable isolates are not shown.](jjm-08-06-16998-i001){#fig20407}

The MRSA isolates belonging to the SCC*mec* type I (66.3%) and type II (65.5%) were greatly recovered from patients in the Intensive Care Unit (ICU), while the SCC*mec* type III was mostly recovered from patients hospitalized on other wards (P \< 0.001). The D-test results revealed that 14 MRSA isolates had inducible resistance to Clindamycin. There was a significant difference regarding the number of the inducible isolates recovered from the two hospitals (13 (92.9%) samples from Faghihi Hospital vs. 1 (7.1%) sample from Nemazee Hospital, P \< 0.001). Also, a significant correlation was observed between susceptibility to Rifampin and inducible Clindamycin resistance because the 13 isolates with inducible resistance remained sensitive to Rifampin (P \< 0.001). DNA sequencing confirmed the presence of the SCC*mec* type I gene with checking through the SCC*mec* database at www.staphylococcus.net/ and using The National Center for Biotechnology Information\'s (NCBI) blast tools, which also revealed that all the isolates were closely related to the COL MRSA strain.

5. Discussion {#sec106749}
=============

In this study, the prevalence of MRSA among the *S. aureus* isolates was found to be 42.3% (146), slightly higher than that in similar reports from the north of Iran, Tehran with 36% ([@A16998R3]). However, the prevalence of MRSA varies widely among different regions and countries; this fact reflects the different infection control policies and other factors involved. Most of the specimens in this study were isolated from sputum (58 = 39.7%) and blood (20 = 13.7%). It is in consistence with the previous studies reporting that MRSA isolates are responsible for the majority of respiratory and blood infections (septicemia, endocarditic, etc.) in hospitalized patients ([@A16998R8], [@A16998R14], [@A16998R15]). Also, a higher frequency of respiratory infections in those studies can indicate that most of the MRSA nosocomial transmissions occurred by the respiratory tract ([@A16998R7], [@A16998R16]).

In this study, the antibiotic susceptibility pattern of the isolates to 13 commonly used antibiotics for MRSA infections was also evaluated. The sensitivity of the entire MRSA isolates to Vancomycin, Linezolid, Teicoplanin, and Synercid^®^ in this study was similar to that in most reports, so these agents can be used as therapeutic choices in our medical centers. Of course, the cost-benefitness and the different pharmacological properties of these agents should be taken into consideration when prescribing antibiotics ([@A16998R8], [@A16998R17]). Chloramphenicol and SXT with sensitivity rates of 97.3% and 76.7%, respectively among our studied isolates, could be considered as the subsequent treatment options. Also, the skin MRSA isolates were more resistant than those of the urine isolates significantly. This may be a reflection of unique bacterial exposure with environmental or specific physiological conditions of these areas. The role of environmental factors such as nurses' hands and clothes in the transmission of resistant isolates on the patient's skin in various studies has been shown previously ([@A16998R18], [@A16998R19]).

In this study, the frequency of induced Clindamycin resistance was detected to be 9.6% among the MRSA isolates. In previous reports in Iran, inducible Clindamycin resistance for MRSA isolates ranged between 2.3% and 33.3% ([@A16998R20]-[@A16998R22]). Also, this frequency has been reported in various rates depending on the geographical distribution from some Asian countries ([@A16998R23], [@A16998R24]). From a total of 146 MRSA isolates tested in this study, the predominant SCC*mec* types were the SCC*mec* type I with a rate of 58.9% (n = 86) and the SCC*mec* type II with a rate of 19.9% (29). These data were similar to the results from a study by Moghadami et al. ([@A16998R4]), who reported type I and II isolation rates of 56.9% and 22%, respectively, as the prevalent SCC*mec* types from 109 MRSA isolates collected from Tehran and Shiraz, Iran. Also, in a hospital survey in the neighboring country, Pakistan, in 2010, the SCC*mec* types I and II were the predominant isolates with 60% and 40% rates, respectively ([@A16998R25]). Some other studies in Iran have also reported the relative prevalence of the SCC*mec* types I and II ([@A16998R26], [@A16998R27]). Fatholahzadeh et al. ([@A16998R3]) and Japoni et al. ([@A16998R8]) in two related studies in Iran reported the SCC*mec* type III as the most predominant type: rates of 98% in the former and 74.3% in the latter. According to previous reports, most of the hospital-acquired MRSA isolates were assigned as the SCC*mec* types I to III, which is consistent with our results ([@A16998R3], [@A16998R4], [@A16998R28]).

The majority of the type I isolates in the present study were from the blood and sputum specimens. It has been previously observed that some plasmin-sensitive surface proteins are located in the specific regions of the SCC*mec* type I elements and are associated with a more efficient distribution of bacteria throughout the body, especially the circulatory system. In some studies, the role of type I MRSA isolates in blood-related diseases has been shown ([@A16998R29], [@A16998R30]). Moreover, in the current study, most of the isolates containing the SCC*mec* type II were isolated from the sputum specimens (44.8%), which is in agreement with the previous investigations suggesting the high frequency of this SCC*mec*-type isolates from respiratory infections ([@A16998R7]). Furthermore, as was mentioned, the prevalence rates of type I (66.3%) and II (65.5%) MRSA isolates were significantly higher (P \< 0.001) in the ICU. It may reflect the fact that some patients such as critically ill patients in the ICU have a greater chance of colonization and infection by these specific SCC*mec* types ([@A16998R31]).

It has been already shown that the SCC*mec* types I to III are frequently isolated from hospital-acquired MRSA and often apart from the *mec*A gene containing additional genes for resistance to several beta-lactam antibiotics ([@A16998R2]). Several reasons to gain additional resistance genes by these isolates have been reported in medical centers ([@A16998R8], [@A16998R32]), which could explain the high antibiotic resistance of the SCC*mec* type I-III isolates in our study. Also, the significant antibiotic susceptibility pattern of certain SCC*mec* type isolates in our results can prompt us to consider these antibiotics as the treatment option for the infection that caused these isolates. In the present study, the majority (about 70 - 80%) of the SCC*mec* type I and II isolates showed susceptibility to SXT, which may be considered to be connected clonally with these isolates ([@A16998R33]). Furthermore, the high prevalence of the SCC*mec* type I isolates observed in the current study with a significantly higher multidrug-resistance (to 7 and 6 antimicrobial agents) indicates that they may adapt and survive in our regional hospitals over time.

Most of the type IV isolates in our study were susceptible to the majority of the tested antibiotics (9 - 10 agents). However, as is indicated in some studies, a few isolates containing type IV cassette were multidrug-resistant in our study as well ([@A16998R7], [@A16998R8]). This suggests that since type IV isolates are often exposed to antibiotics, they could gain antibiotic resistance genes other than the *mec*A gene to survive in medical centers ([@A16998R8], [@A16998R34]). The frequency of the SCC*mec* type I isolates in the present study can indicate the emergence of this type in the studied medical centers. As was previously mentioned in our results, due to the significant clinical source and the antimicrobial susceptibility pattern of different SCC*mec* type isolates, optimizing institutional infection control policies for preventing MRSA transmission among hospitalized patients should be considered. Our findings highlight the importance of the continual monitoring of molecular changes with regard to the related susceptibility patterns of isolates to commonly clinically used antibiotics in our region.
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